Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Study of BNC105P in Combination With Everolimus or Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma Following Prior Tyrosine Kinase Inhibitors

NCT01034631 is registered in ClinicalTrials.gov with Hoosier Cancer Research Network as lead sponsor.

NCT NCT01034631
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01034631 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Study of BNC105P in Combination With Everolimus or Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma Following Prior Tyrosine Kinase Inhibitors
Lead sponsor
Hoosier Cancer Research Network
Phase
Phase 1/2
Overall status
Completed
Start date
January 31, 2010
Completion date
December 31, 2016
Enrollment
154 (actual)
Sites
108

Conditions

As the registry lists them; a condition with its own page is linked.

renal cell carcinoma